Hendrick Health participating in SPIRIT XLV PAS stent study

The Hendrick Center for Research is participating in an international post-approval study (PAS) of a stent for the treatment of coronary artery disease (CAD).

Three patients at Hendrick Medical Center recently were enrolled in the SPIRIT XLV PAS study of the XIENCE Skypoint Stent System manufactured by Abbott and approved by the Federal Drug Administration (FDA) for commercial use to treat CAD. The purpose of the study is to evaluate the continued safety and effectiveness of the stent system of 4.5 mm and 5.0 mm diameter.

After being approved as a study site in August, Hendrick Medical Center enrolled its first study patients in October. Principal investigator is cardiologist Dr. Joji Varghese. The study is now closed to enrollment because the enrollment goal set by the sponsor was reached.

The Hendrick Center of Research is managing the health system’s participation is several clinical trials in not only cardiology but also infectious disease, respiratory/surgical and oncology.

To help advance healthcare and expand early access to new technology, medications and devices for improving patient outcomes, Hendrick Health offers phase 3 clinical trials and phase 4 observation trials. The health system established an oncology research program in 2011 and expanded in 2020 with the creation of a research department to participate in trials in other medical disciplines. In 2023, the program was renamed Hendrick Center for Research.